Fullerton Fund Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Fullerton Fund Management’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$254K	Sell	568 -332	-37%	-$155K	0.02%	108
2025 Q4	$408K	Sell	900 -622	-41%	-$268K	0.02%	91
2025 Q3	$596K	Buy	+1,522	New	+$636K	0.02%	77
2025 Q2	–	Sell	-1,028	Closed	-$498K	–	129
2025 Q1	$498K	Buy	+1,028	New	+$479K	0.03%	83
2024 Q4	–	Sell	-1,153	Closed	-$536K	–	125
2024 Q3	$536K	Sell	1,153 -56	-5%	-$26.9K	0.02%	82
2024 Q2	$567K	Hold	1,209	–	–	0.03%	69
2024 Q1	$505K	Buy	+1,209	New	+$511K	0.02%	72

Other funds holding VRTX

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Fullerton Fund Management's VRTX Position: Q1 2026 in Review

Fullerton Fund Management reduced its Vertex Pharmaceuticals (VRTX) stake by 37% in Q1 2026, selling an estimated $155K and leaving 568 shares worth $254K. The position accounts for 0.02% of the portfolio, ranked #108.

Fullerton Fund Management first reported a position in VRTX in Q1 2024 and has held it in 7 quarters since. The position peaked at $596K in Q3 2025. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

Fullerton Fund Management held 568 shares of Vertex Pharmaceuticals worth $254K as of Q1 2026.
Fullerton Fund Management sold 332 Vertex Pharmaceuticals shares in Q1 2026, an estimated $155K.
Vertex Pharmaceuticals made up 0.02% of Fullerton Fund Management's portfolio in Q1 2026, its #108 holding.
Fullerton Fund Management first reported a position in Vertex Pharmaceuticals in Q1 2024 and has held it in 7 quarters since.
Fullerton Fund Management's Vertex Pharmaceuticals position peaked at $596K in Q3 2025.
1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on Fullerton Fund Management's 13F filing for Q1 2026, filed 15 May 2026.